The serine/threonine kinase tumor progression locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF␣, IL-1, and IFN␥. We previously demonstrated that Tpl2 regulates T cell receptor (
The serine-threonine kinase, tumor progression locus 2 (Tpl2 or Map3k8/Cot), is a potent inflammatory mediator that drives the production of TNF alpha, IL-1 beta, and IFN gamma. We previously demonstrated that Tpl2 modulates TCR signaling and T helper cell differentiation. However, little is known about how Tpl2 alters the development or function of regulatory T cells (Tregs). Tregs are a specialized subset of T cells that express Foxp3 and possess immunosuppressive properties. Because of Tpl2’s role in promoting inflammation, we hypothesized that Tpl2 inhibits Treg development and immunosuppressive functions. Tpl2−/− naïve CD4 T+ cells preferentially differentiated into Foxp3+ inducible Tregs in vitro as well as in vivo in a murine model of OVA-induced systemic tolerance. Treg biasing in Tpl2−/− T cells depended upon the TCR signal strength and correlated with reduced activation of the Akt/mTOR/S6 pathway. Importantly, freshly isolated Tpl2−/− Tregs had increased expression of Foxp3 and immunosupressive cytokines IL-10 and IL-35 and were more suppressive in a T cell transfer model of colitis, as evidenced by reduced accumulation of inflammatory T effectors, systemic inflammatory cytokines TNF, IL-6 and IFN gamma, and colonic inflammation. Therefore, Tpl2 promotes inflammation in part by limiting Foxp3 expression, iTreg differentiation and immunosuppressive functions. These findings suggest that Tpl2 inhibition may be used to preferentially drive Treg induction and limit inflammation in autoimmune diseases.
Regulatory T cells (Tregs) are a specialized subset of immunosuppressive T cells that function to maintain peripheral tolerance. We previously demonstrated that the serine-threonine kinase, tumor progression locus 2 (Tpl2, also designated Cot/Map3k8), regulates TCR signaling and inflammatory cytokine secretion in CD4+ T cells. Herein, we demonstrate that Tpl2 is preferentially expressed by Tregs and regulates their development and functions. Tpl2-/- mice exhibited increased proportions of thymic natural Tregs (nTregs) as well as peripheral splenic Tregs, in vivo. Enhanced Treg development was due to a T cell autonomous defect, since Treg development from tpl2-/- naïve T cells cultured in vitro was similarly enhanced, and peripheral Treg proportions were also increased within the tpl2-/- donor compartment of mixed bone marrow chimeras. This defect depended upon TCR signal strength and was enhanced at low antigen concentrations. Importantly, tpl2-/- Tregs had increased expression of the immunosupressive cytokines, IL-10 and IL-35, and provided better protection than wild-type Tregs in vivo in a T cell transfer model of colitis. These results demonstrate that Tpl2 has an important physiological role in limiting Foxp3 expression, Treg development and functions. Therefore, Tpl2 inhibition could potentially be used to deviate pathological immune responses in a variety of autoimmune diseases towards a protective, tolerogenic response through preferential Treg induction.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.